drugset / Trial / NCT05806060
Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The study is being conducted to evaluate VEGFR BP102 with nab-paclitaxe or treatment of physician's choice (TPC) versus nab-paclitaxe or TPC in patients for basal-like immune suppressed (BLIS) subtype of triple-negative breast cancer (TNBC) in the first-line teatment of unresectable locally advanced or metastatic TNBC.
Timeline
- Start
- 2023-04-25
- Primary completion
- 2026-05-01
- Completion
- 2026-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Comparator | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Comparator | Carboplatin | Small molecule | 6 unknown | Intravenous |
| Comparator | Epothilone D | Small molecule | 30 mg/m2 | Intravenous |
| Comparator | Eribulin | Small molecule | 1.4 mg/m2 | Intravenous |
| Comparator | TPC | Unknown | 100 mg/m2 | — |
| Comparator | Vinorelbine | Small molecule | 25 mg/m2 | Intravenous |
| Background | nab-Palitaxel | Unknown | 100 mg/m2 | — |